Andrea Sartore-Bianchi
Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer.
Overview
Andrea Sartore-Bianchi is a medical oncologist at the Niguarda Cancer Center in Milan. He was first author of the 2016 Lancet Oncology report of HERACLES, the phase 2 trial in which trastuzumab plus lapatinib produced responses in about a third of patients with heavily pretreated HER2-amplified, KRAS wild-type metastatic colorectal cancer, establishing HER2 as a target in the disease. His research covers resistance to anti-EGFR antibodies and molecular selection for therapy.
Similar pages
not linked directly; found by shared links- PersonSalvatore Siena
Shares Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, HERACLES, HER2-amplified colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonJohn H. Strickler
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonRona Yaeger
Shares Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonGerald W. Prager
Shares Colorectal cancer and the tags colorectal, trialist.
- PersonScott Kopetz
Shares Colorectal cancer and the tags colorectal, targeted-therapy.
- PersonAleksandar Sekulic
Shares the tags targeted-therapy, trialist.
- PersonAlice T. Shaw
Shares the tags targeted-therapy, trialist.
- PersonEric Jonasch
Shares the tags targeted-therapy, trialist.